地奥心血康软胶囊联合沙库巴曲缬沙坦治疗缺血性心肌病的疗效及对心室重构、生存质量的影响  

Therapeutic effect of Di'ao Xinxuekang soft capsule combined with Shakubaqu valsartan in the treatment of ischemic cardiomyopathy and their impact on ventricular remodeling and quality of life

作　　者：袁正华[1] 柏玉顺 袁先琢 YUAN Zheng-hua;BAI Yu-shun;YUAN Xian-zhuo(Department of Cardiovascular,Chuzhou Hospital of Integrated Traditional Chinese and Western Medicine,Chuzhou Anhui 239000,China)

机构地区：[1]滁州市中西医结合医院心血管科,安徽滁州239000

出　　处：《临床和实验医学杂志》2024年第4期349-353,共5页Journal of Clinical and Experimental Medicine

基　　金：安徽省中医药传承创新科研项目(编号:2020ccyb27)。

摘　　要：目的探讨地奥心血康软胶囊联合沙库巴曲缬沙坦治疗缺血性心肌病的疗效及对心室重构、生存质量的影响。方法回顾性选取2018年9月到2023年9月滁州市中西医结合医院收治的80例缺血性心肌病患者,依据治疗方法的不同将其分为对照组与观察组,每组各40例。对照组应用沙库巴曲缬沙坦治疗,观察组应用地奥心血康软胶囊联合沙库巴曲缬沙坦治疗。治疗3个月后,比较两组患者临床疗效,比较两组患者治疗前、治疗3个月后的血液生化指标[B型脑钠肽(BNP)、高敏C反应蛋白(hs-CPP)、超氧化物歧化酶(SOD)]、Killip心功能分级、心室重构相关指标[左心室重构指数(LVRI)、左心室质量指数(LVMI)]水平,以及明尼苏达心力衰竭生存质量问卷(MLHFQ)评分。结果治疗3个月后,观察组治疗总有效率为95.00%,高于对照组(75.00%),差异有统计学意义(P<0.05)。治疗3个月后,两组患者BNP、hs-CPP水平均较治疗前降低,SOD水平均较治疗前升高,且观察组BNP、hs-CPP水平分别为(93.28±8.62)pg/L、(29.12±4.12)mg/L,均明显低于对照组[(125.61±10.69)pg/L、(37.12±4.25)mg/L],SOD水平为(108.27±10.69)nU/mL,高于对照组[(93.67±15.45)nU/mL],差异均有统计学意义(P<0.05)。观察组治疗3个月后,患者Ⅰ级比率为47.50%,高于对照组(25.00%),Ⅲ级、Ⅳ级比率为7.50%、0,明显低于对照组(25.00%、10.00%),差异均有统计学意义(P<0.05)。观察组LVRI、LVMI为(2.52±0.43)g/mL、(93.43±7.17)g/m^(2),均低于对照组[(2.94±0.24)g/mL、(110.31±11.28)g/m^(2)],差异有统计学意义(P<0.05)。治疗3个月后,两组患者MLHFQ中身体领域、情绪领域、其他领域各分值及MLHFQ总分均较治疗前升高,且观察组身体领域、情绪领域、其他领域各分值及MLHFQ总分分别为(32.56±7.11)、(20.36±4.25)、(33.93±5.13)、(86.87±8.37)分,均高于对照组[(27.87±5.13)、(17.56±4.46)、(30.01±4.05)、(75.44±5.66)分],差异均有统计学意义(P<0.05)。结�Objective To explore the therapeutic effect of Di'ao Xinxuekang soft capsule combined with Shakubaqu valsartan in the treatment of ischemic cardiomyopathy,as well as their impact on ventricular remodeling and quality of life.Methods This study was a retrospective analysis,80 patients with ischemic cardiomyopathy admitted to Chuzhou Hospital of Integrated Traditional Chinese and Western Medicine from September 2018 to September 2023 were selected.According to the different treatment methods,they were divided into the control group and the observation group,with 40 cases in each group.The control group were treated with Shakubaqu valsartan,while the observation group were treated with Di'ao Xinxuekang soft capsule combined with Shakubaqu valsartan.The clinical efficacy of two groups of patients was compared,the levels of blood biochemical indicators[B-type natriuretic peptide(BNP),high sensitivity C-reactive protein(hs-CPP),superoxide dismutase(SOD)],Killip cardiac function grading,left ventricular remodeling indexs[left ventricular remodeling index(LVRI) and left ventricular mass index(LVMI)],and Minnesota Heart Failure Quality of Life Questionnaire(MLHFQ) of the two groups of patients before treatment and after 3 months of treatment were compared.Results After 3 months of treatment,the total effective rate of the observation group was 95.00%,which was higher than that of the control group(75.00%),and the difference was statistically significant(P<0.05).After 3 months of treatment,the levels of BNP and hs-CPP in two groups of patients were lower than those before treatment,while the levels of SOD were higher than those before treatment,and the levels of BNP and hs-CPP in the observation group were(93.28±8.62) pg/L and(29.12±4.12) mg/L,respectively,which were significantly lower than those in the control group [(125.61±10.69) pg/L and(37.12±4.25) mg/L],and the level of SOD was(108.27±10.69) nU/mL,which was higher than that in the control group [(93.67±15.45) nU/mL],and the differences were statistically signi

关 键 词：缺血性心肌病 动脉粥样硬化 地奥心血康软胶囊 沙库巴曲缬沙坦 心室重构 生存质量 心功能 

分 类 号：R542.2[医药卫生—心血管疾病]